Year All2024202320222021 Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy 04-17-2023 Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy 04-04-2023 Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors 03-30-2023 Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders 03-15-2023 Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates 03-07-2023 Zevra Therapeutics to Present at 35th Annual Roth Conference 03-06-2023 Zevra Therapeutics Begins Trading as ZVRA 03-01-2023 Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD) 02-28-2023 Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy 02-27-2023 Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results 02-27-2023
Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy 04-17-2023
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates 03-07-2023
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD) 02-28-2023